---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-24-000045"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2024-06-17T23:59:59+00:00"
generated_at: "2026-06-01T04:13:19.655509+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Shareholders approve 9.7M share stock plan amendment, re-elect all eight directors

## Summary
- All eight director nominees re-elected to one-year terms; votes for ranged from 12.3M to 15.3M.
- Ratification of Ernst & Young as independent auditor for FY2024 approved (15.9M for, 0.8M against).
- Non-binding advisory say-on-pay resolution approved with 14.3M votes for.
- Restated 2002 Stock Incentive Plan approved, authorizing up to 9,713,754 common shares.
- Company will cease granting awards under the 2022 Employment Inducement Plan after meeting date.

## SEC filing metadata
- accession: 0000886163-24-000045
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2024-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616324000045/0000886163-24-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616324000045/lgnd-20240614.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-24-000045
- JSON: https://secwatch.observer/filing/0000886163-24-000045.json
- Plain text: https://secwatch.observer/filing/0000886163-24-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.